Introduction {#section1-1756286420936166}
============

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS). Several factors implicate chromosomal sex and hormones in susceptibility and disease course in MS. MS is more common in women, with a female to male sex ratio of 3:1,^[@bibr1-1756286420936166]^ whereas before puberty and after menopause the sex ratio approaches 1:1.^[@bibr2-1756286420936166][@bibr3-1756286420936166]--[@bibr4-1756286420936166]^ MS most commonly begins between 20 years and 40 years of age, and thus women of reproductive age are most commonly affected.

Whereas relapse rate decreases during pregnancy, there tends to be an increased relapse rate postpartum,^[@bibr5-1756286420936166]^ and relapse rate decreases after menopause.^[@bibr6-1756286420936166]^ Management of women with MS throughout their reproductive lifespan requires consideration of effects of pregnancy and breastfeeding, including understanding disease-modifying therapy (DMT) effects on children of women with MS. Hormonal factors may influence disability progression, as progression tends to occur earlier in men,^[@bibr7-1756286420936166]^ and later during the perimenopausal period in women.^[@bibr8-1756286420936166],[@bibr9-1756286420936166]^

In this review, we discuss effects of sex on disease susceptibility, implications of MS on fertility and pregnancy, including peripartum DMT and other management considerations, the impact of pregnancy on the course of MS, the interaction between reproductive aging and MS, and sexual dysfunction in women with MS.

Susceptibility to MS {#section2-1756286420936166}
====================

It has long been recognized that MS is more common in women, but recent observations suggest the sex ratio may be increasing due to a rise in cases in women over the last century.^[@bibr10-1756286420936166]^ An increasing sex ratio has been reported in several countries (e.g., in Canada the sex ratio increased from 1.9 to 3.2, and in Sweden from 1.7 to 2.7 for patients born in the 1930s compared with the 1980s).^[@bibr1-1756286420936166],[@bibr11-1756286420936166]^ However, there appear to be regional differences in the changing sex ratio as this has not been observed in New Zealand,^[@bibr12-1756286420936166]^ and may differ by latitude.^[@bibr13-1756286420936166]^ More recently, the sex ratio was stable in Ontario, Canada for MS onset from 1996 to 2013.^[@bibr14-1756286420936166]^ A rise in incidence over the last century is too short for a genetic cause and suggests a sex by environmental factor interaction. While some question whether the rising incidence is confounded by better diagnostics, others urge searching for an environmental cause of the observed increased incidence in women. There have been many changes in women's lifestyles in recent decades: a later age at first pregnancy, increased availability and use of hormonal contraception, a lower rate of childbirth, and higher rates of employment and smoking.

Many of these factors have been examined in the Danish MS Registry.^[@bibr15-1756286420936166]^ Having children reduced the risk of MS in women (but not in men) by about 46% during the following 5 years. This may be due to temporary immunosuppression during pregnancy, although reverse causation secondary to an "MS prodrome" resulting in fewer pregnancies in women with subclinical MS cannot be excluded.^[@bibr16-1756286420936166]^

It is likely that the increased susceptibility of women towards MS is influenced by genetic, hormonal, and environmental factors.

Genetics and epigenetics {#section3-1756286420936166}
------------------------

The genetic predisposition of MS is approximately 25%, based on monozygotic twin studies.^[@bibr17-1756286420936166]^ With the success of genome wide association studies (GWAS) over the last decade, 48% of this heritability has been explained with 233 statistically independent loci (32 in the MHC region).^[@bibr18-1756286420936166]^ Carrying *HLA-DRB1\*15:01* accounts for 10.5% of the genetic risk for MS.

Leveraging the largest GWAS of nearly 50,000 MS cases, one single nucleotide polymorphism (SNP rs2807267, closest gene *VGLL1*) on the X chromosome has been associated with MS.^[@bibr18-1756286420936166]^ The SNP lies within an enhancer peak specific for T cells, and additional study is required to understand its functional consequence in MS. No susceptibility alleles have been identified on the Y chromosome.

Interaction between the genome and sex-specific biological and environmental factors may underlie at least part of the possible increase in MS incidence in women. One aspect of this may be sex-specific epigenetic changes. Maternal imprinting of the X chromosome or X dosage effects may contribute to autoimmunity in women.^[@bibr19-1756286420936166]^ Voskuhl *et al.* demonstrated differential methylation and expression of genes on the X chromosome in T lymphocytes from females *versus* males.^[@bibr20-1756286420936166],[@bibr21-1756286420936166]^ In addition, an X chromosome gene (*Kdm6a*) that escapes X inactivation, with two copies expressed in females and one in males, is a histone demethylase that influences autosomal genome wide expression and is proinflammatory in T lymphocytes.^[@bibr22-1756286420936166]^ It is thus conceivable that a key environmental factor, which has changed over the last century, may interact with genes on either sex chromosomes or autosomes to create increased risk in women.

Hormones {#section4-1756286420936166}
--------

The effects of puberty, pregnancy, and menopause -- periods during which sex hormone levels change dramatically -- have been the subject of several studies. Puberty represents a risk factor for MS; earlier age of menarche has been associated with increased risk of MS and younger onset of MS symptoms in women.^[@bibr23-1756286420936166],[@bibr24-1756286420936166]^ In pediatric MS, girls largely present 2 years after menarche^[@bibr25-1756286420936166]^; the immune system may be stimulated by sex steroid hormones during puberty.^[@bibr26-1756286420936166]^ Additional work is needed to parse out the specific biological mechanism of the epidemiologic association of puberty with MS risk. As mentioned previously, nulliparous women may have higher risk of MS than those who had several pregnancies.^[@bibr15-1756286420936166]^ To reconcile this increased risk with female puberty onset and decreased risk with multiparity, estrogens have been shown to have a biphasic dose effect, being immunostimulatory at low levels consistent with menstrual cycling, while being immunosuppressive at high levels of pregnancy.^[@bibr27-1756286420936166],[@bibr28-1756286420936166]^

Environmental {#section5-1756286420936166}
-------------

Environmental factors likely play a large role in MS risk given the 75% discordance rate amongst identical twins.^[@bibr17-1756286420936166]^ The most replicated environmental risk factors for MS include: active and passive smoking, Epstein Barr virus (EBV) seropositivity, low serum levels of vitamin D, and low sunlight exposure. Biological sex may interact with some of these factors to increase MS risk.

### Smoking {#section6-1756286420936166}

Smokers of both sexes have increased risk of developing MS (odds ratio 1.4); risk increases with cumulative smoking dose.^[@bibr29-1756286420936166],[@bibr30-1756286420936166]^ Data from The Swedish National Institute of Public Health showed that, at the beginning of the 21st century, 20--25% women smoked (compared with 15--17% men). United Kingdom (UK) smoking prevalence has been increasing in women throughout the 20th century, which has been hypothesized to contribute to increasing MS risk.^[@bibr31-1756286420936166]^

### EBV {#section7-1756286420936166}

EBV is a ubiquitous gamma herpes virus. In adulthood, \~95% of the general population have evidence of prior EBV exposure; this proportion approaches 100% in MS.^[@bibr32-1756286420936166]^ While, on average, men seroconvert to positive EBV status at a slightly later age than women, there is no clear evidence that EBV plays a role in driving the unequal sex ratio of MS.

### Vitamin D/sunlight exposure {#section8-1756286420936166}

The move away from outdoor-based lifestyles may be driving a reduction in serum vitamin D levels in the population. It is not known if women are more susceptible to downstream effects of low vitamin D,^[@bibr33-1756286420936166]^ but a study in an animal model demonstrated protection from experimental autoimmune encephalitis (EAE) with vitamin D only in female mice.^[@bibr34-1756286420936166]^ Low sunlight exposure is also associated with MS risk, with potential sex-specific effects of ultraviolet radiation exposure.^[@bibr35-1756286420936166]^

More data are needed to identify hormonal and environmental risk factors for MS, which act preferentially in women.

Fertility and contraception {#section9-1756286420936166}
===========================

Fertility and assisted reproductive technology {#section10-1756286420936166}
----------------------------------------------

There are no studies that directly assess pregnancy success rates in MS,^[@bibr36-1756286420936166],[@bibr37-1756286420936166]^ though some epidemiological studies have shown that women with MS may have fewer children than the general population.^[@bibr36-1756286420936166],[@bibr38-1756286420936166],[@bibr39-1756286420936166]^ Potential underlying reasons for this could include the effect of autoimmune disease on fertility, the contributions of symptoms such as fatigue, sexual dysfunction, and bladder impairment on attempting pregnancy, or the individual's decision to conceive being influenced by her disease.^[@bibr36-1756286420936166],[@bibr37-1756286420936166],[@bibr40-1756286420936166]^ Certain older DMTs, particularly cyclophosphamide and mitoxantrone,^[@bibr41-1756286420936166],[@bibr42-1756286420936166]^ may also impair fertility. Rigorous analyses for newer drugs are limited. More recent studies have assessed markers of ovarian reserve and function in women with MS, including levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and anti-Mullerian hormone (AMH), and antral follicle count.^[@bibr9-1756286420936166],[@bibr43-1756286420936166],[@bibr44-1756286420936166]^ In one study of 76 women with relapsing MS (most of whom were not taking DMT) and 58 controls, women with MS had reduced ovarian reserve (lower AMH level) compared with healthy controls.^[@bibr43-1756286420936166]^ Another study showed those with higher disease activity had lower AMH levels than those with lower disease activity.^[@bibr44-1756286420936166]^ However, in a study of 412 women with MS \[mostly relapsing remitting (RRMS) and using injectable therapies\] and 180 healthy controls, there was no difference in AMH level for women with MS compared with controls after adjustment for chronological age, birth control/hormonal therapy use, body mass index (BMI), and smoking.^[@bibr9-1756286420936166]^

Regardless of any potential impact of MS on fertility, 12% of women in the general population confront infertility and may turn to assisted reproductive technologies (ART).^[@bibr45-1756286420936166]^ ART involves administration of hormonal medications, and may include several procedures *in vitro* on oocytes and sperm, or on embryos, to establish a pregnancy. Artificial insemination (INSE) may be performed either with *in vitro* fertilization (IVF) or intracytoplasmic sperm injection (ICSI).^[@bibr46-1756286420936166]^ Although the effect of ART on the immune system in women with MS requires further study, there are reports of increased MS activity after ART ([Table 1](#table2-1756286420936166){ref-type="table"}).^[@bibr47-1756286420936166][@bibr48-1756286420936166][@bibr49-1756286420936166]--[@bibr50-1756286420936166]^ Hellwig *et al.* observed that 12 of 23 women with MS relapsed within 3 months after ART, and the difference in relapse rate pre- and post-ART was correlated with INSE procedure.^[@bibr51-1756286420936166]^ A small study of women treated with GnRH (gonadotropin releasing hormone) agonists and recombinant FSH observed increased clinical relapses and enhancing magnetic resonance imaging (MRI) lesions after ART.^[@bibr52-1756286420936166]^ Similarly, another study, wherein women with MS received GnRH agonist or antagonist, followed by FSH, found that the annualized relapse rate (ARR) increased during 3 months following ART, with correlation to GnRH agonist use and IVF failure.^[@bibr53-1756286420936166]^ A recent meta-analysis by Bove *et al.*^[@bibr50-1756286420936166]^ combined five published studies and reported a case series (*n* = 12).^[@bibr51-1756286420936166][@bibr52-1756286420936166][@bibr53-1756286420936166][@bibr54-1756286420936166]--[@bibr55-1756286420936166]^ Whereas the Boston case series did not have higher ARR after ART compared with before, the overall meta-analysis including this cohort confirmed increased ARR after ART, with a mean ARR increase of 0.92 \[95% confidence interval (CI) 0.33--1.51\].^[@bibr50-1756286420936166]^ On the other hand, Guzman-Soto *et al.* reported that leuprolide acetate, a synthetic analogue of GnRH used in IVF, has a neurotrophic effect on neurofilament, myelin basic protein expression, and axonal morphometry in EAE, thus opening horizons for studying protocols of ART in MS.^[@bibr56-1756286420936166]^

###### 

Summarized data from articles reporting on ART in women with MS.

![](10.1177_1756286420936166-table2)

  Authors                                                 Year   Type of article   Main findings
  ------------------------------------------------------- ------ ----------------- ------------------------------------------------------------------------------------
  Cavalla *et al.*^[@bibr36-1756286420936166]^            2006   Review            Review on fertility in women with MS
  D'Hooge *et al.*^[@bibr57-1756286420936166]^            2013                     Review on reproductive factors in women with MS
  Hellwig and Correale^[@bibr58-1756286420936166]^        2013                     Immunological changes induced by ART can increase pro-inflammatory factors in MS
  Laplaud *et al.*^[@bibr54-1756286420936166]^            2006   Case series       GnRH agonists correlated to relapses
  Laplaud *et al.*^[@bibr59-1756286420936166]^            2007                     GnRH agonists correlated to relapses
  Hellwig *et al.*^[@bibr55-1756286420936166]^            2008                     GnRH agonists correlated to relapses
  Hellwig *et al.*^[@bibr51-1756286420936166]^            2009                     Hormonal approach did not correlate to relapses
  Correale *et al.*^[@bibr52-1756286420936166]^           2012                     GnRH agonists correlated to relapses
  Michel *et al.*^[@bibr53-1756286420936166]^             2012                     GnRH agonists correlated to relapses
  Bove *et al.*^[@bibr50-1756286420936166]^               2019   Meta-analysis     Meta-analysis of above studies confirmed increased ARR after ART *versus* prior
  Vaknin-Dembinsky *et al.*^[@bibr47-1756286420936166]^   2015   Case reports      Relapse and tumefactive lesion shortly after an IVF cycle
  Ladwig *et al.*^[@bibr48-1756286420936166]^             2016                     Onset of MS after IVF
  Torkildsen *et al.*^[@bibr49-1756286420936166]^         2018                     Severe reactivation of MS following IVF
  Voskuhl et al.60                                        2012   Editorial         Hormonal manipulation in ART is complex and may induce changes in immunomodulation

ARR, annualized relapse rate; ART, assisted reproductive technology; GnRH, gonadotropin releasing hormone; IVF, *in vitro* fertilization; MS, multiple sclerosis.

In summary, ART, particularly the use of GnRH agonists, may increase MS disease activity in the short term, though further work is necessary to elucidate how induced hormonal changes may affect MS course.

Contraception {#section11-1756286420936166}
-------------

Contraception is an important topic in MS, particularly as women are often of childbearing age at disease onset and some DMTs are potential teratogens.^[@bibr61-1756286420936166]^ Multiple dimensions should be considered, including contraception effect on risk of MS and related disability, family planning, type of contraception available, and concurrent use with DMTs.

Prior studies have reported mixed effects of hormonal contraception on risk of developing MS.^[@bibr62-1756286420936166][@bibr63-1756286420936166][@bibr64-1756286420936166][@bibr65-1756286420936166][@bibr66-1756286420936166]--[@bibr67-1756286420936166]^ Different population-based, case-control, or cohort studies concluded a protective,^[@bibr65-1756286420936166],[@bibr66-1756286420936166]^ neutral,^[@bibr64-1756286420936166]^ or even negative effect of oral contraceptive (OC) exposure on MS risk.^[@bibr67-1756286420936166]^ While the Nurses' Health Study showed no effect of past or current use of OC on risk of MS,^[@bibr64-1756286420936166]^ a case-control study demonstrated decreased risk of MS in those using OC in the 3 years prior to MS onset,^[@bibr65-1756286420936166]^ and the Swedish MS registrar demonstrated that OC use before first MS symptoms was associated with an older age of MS onset.^[@bibr66-1756286420936166]^ On the other hand, a nested case-control study suggested a slightly increased risk of MS or clinically isolated syndrome (CIS) with former or current OC exposure, although this could have been due to an unmeasured confounder.^[@bibr67-1756286420936166]^ Limitations of most of these studies include observational design, small sample size, self-reported data on OC use, lack of information about OC hormonal composition and duration of exposure, and the potential for residual confounding. As such, definitive conclusions on the effect of OC on MS risk remains unclear.

There is scarce information about the effect of OC on long-term prognosis of MS, although, reassuringly, hormonal contraception does not seem to negatively affect disease progression or disability.^[@bibr68-1756286420936166]^ Two studies reported decreased risk of disability accumulation and conversion to secondary progressive MS (SPMS) in relapsing onset patients who had ever used OC.^[@bibr69-1756286420936166],[@bibr70-1756286420936166]^ No significant differences in ARR between OC ever and never users were found. In contrast, D'Hooghe *et al.* described a shorter time from first symptom to reach Expanded Disability Status Scale (EDSS) 6.0 in OC users with primary progressive MS (PPMS).^[@bibr71-1756286420936166]^ The lack of consistency between studies could be partially explained by the influence of potential confounders that affect disease evolution and also determine the patient's decision to take OC. Recently, a multivariable and time-dependent analysis applied to the Barcelona CIS cohort reported that OC use before or after CIS did not significantly influence the risk of MS or time to confirmed EDSS 3.0.^[@bibr72-1756286420936166]^ However, OC may have an impact in patients with established MS distinct to any effect on ARR due to transition from the more inflammatory early stage of disease to the more neurodegenerative stage, which may be more sensitive to neuroprotective effects of estrogens in OC.^[@bibr73-1756286420936166]^

Optimal contraceptive methods should be individualized, as women with MS may suffer from symptoms that make use of some methods difficult (such as using vaginal rings).^[@bibr74-1756286420936166]^ The US Medical Eligibility Criteria for Contraceptive Use, published by the United States (US) Centers for Disease Control and Prevention, outlines the safety of contraception in women with MS, and generally, the majority are felt to be safe in MS. Caution should be exercised in the use of combined hormonal contraceptives in individuals with prolonged immobility, due to increased thromboembolic risk.^[@bibr75-1756286420936166]^ Current DMTs do not appear to alter effectiveness of hormonal contraceptives,^[@bibr74-1756286420936166],[@bibr76-1756286420936166]^ but there are limited formal drug--drug interaction studies, and symptomatic medications such as modafinil can decrease effectiveness of hormonal contraceptives.^[@bibr74-1756286420936166]^

Immunology of pregnancy: effects in MS {#section12-1756286420936166}
======================================

Immunological changes at the maternal--fetal interface {#section13-1756286420936166}
------------------------------------------------------

The maternal--fetal interface refers to the collocation between the uterus and extra-embryonic tissue.^[@bibr77-1756286420936166]^ On the fetal side, the blastocyst differentiates into an inner cell mass, the future fetus, and the outer extra-embryonic trophoblast. The trophoblast further separates into villous and non-villous cytotrophoblast and syncytiotrophoblast.^[@bibr77-1756286420936166]^ In preparation for potential conception, the endometrium undergoes a series of changes, or decidualization, that continue into pregnancy.^[@bibr78-1756286420936166]^ Decidualization requires a number of immune cells allowing trophoblast invasion (resulting in maternal--fetal interface), remodeling of spiral arteries, and placentation.^[@bibr77-1756286420936166]^ Decidualization is also important in the development of anti-microbial immunity.^[@bibr79-1756286420936166]^

Immunological changes in pregnancy and MS {#section14-1756286420936166}
-----------------------------------------

Pregnancy affords protection from relapses in EAE and MS.^[@bibr5-1756286420936166],[@bibr80-1756286420936166],[@bibr81-1756286420936166]^ Hormonal changes induced by pregnancy modulate immune response toward a state of tolerance to allow the semi-allogenic fetus to grow within the maternal uterus. Estrogen, progesterone, and human chorionic gonadotropin (hCG) modulate cells of the innate and adaptive immune system to adopt fetal-friendly phenotypes.^[@bibr82-1756286420936166]^ A shift from Th1 to Th2 response has been observed consistently in MS pregnancies,^[@bibr83-1756286420936166][@bibr84-1756286420936166]--[@bibr85-1756286420936166]^ based on studies between 13 weeks and 27 weeks gestation. More recent data suggests active pro-inflammatory Th1 immunity before and after this period.^[@bibr79-1756286420936166]^ Regulatory T cells (Tregs) have been found to be increased,^[@bibr86-1756286420936166],[@bibr87-1756286420936166]^ decreased,^[@bibr88-1756286420936166]^ or unchanged,^[@bibr89-1756286420936166],[@bibr90-1756286420936166]^ probably due to different definitions of Tregs used across studies. The Th17 compartment seems unaffected by pregnancy,^[@bibr88-1756286420936166]^ whereas CD56^bright^ natural killer (NK) cells were increased peripherally in one study.^[@bibr88-1756286420936166]^

In MS, pregnancy also alters the clonal composition of T cells toward a more uniformly distributed repertoire.^[@bibr91-1756286420936166]^ It induces a contraction of relapse-associated T cell clones, potentially contributing to reduced relapse rate from the first to third trimester.^[@bibr91-1756286420936166]^ Such clones re-expand after delivery in an individualized fashion.^[@bibr91-1756286420936166]^ Women gradually recover pre-pregnancy immunity along with decreased pregnancy hormones postpartum, which may lead to disease rebound, although immunological mechanisms are unclear. Tregs changed functionally in the early postpartum period in MS in one study,^[@bibr89-1756286420936166]^ and decreased numerically in another study.^[@bibr88-1756286420936166]^ Decline in CD4+, interferon-γ producing T cells, as well as in CD56^bright^ NK cells,^[@bibr89-1756286420936166]^ has been correlated with postpartum MS relapses.^[@bibr92-1756286420936166]^ Although the immunopathogenic role of B cells is increasingly recognized, and these cells are sensitive to stimulation by female sex hormones,^[@bibr93-1756286420936166]^ there is a paucity of studies exploring whether they are modulated by pregnancy. Further studies investigating functional changes of immune cell subtypes are required to clarify complex relationships between pregnancy and immunomodulation. Indeed, the immune system during pregnancy is dynamic and responsive, promoting tolerance to fetal proteins and allowing fetal growth.^[@bibr79-1756286420936166],[@bibr89-1756286420936166],[@bibr94-1756286420936166]^ [Table 2](#table3-1756286420936166){ref-type="table"} summarizes immunological changes by pregnancy trimester and effects on MS.

###### 

Immunological changes by pregnancy trimester and effects on MS.

![](10.1177_1756286420936166-table3)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                First trimester of pregnancy (post-ovulation to \<13 weeks GA)                                                                                                                                                                       Second trimester of pregnancy (13--27 weeks GA)                                                                                                                                       Third trimester of pregnancy (\>27--40 weeks GA)
  ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  Main event                    Implantation and placentation^[@bibr77-1756286420936166],[@bibr79-1756286420936166]^                                                                                                                                                 Symbiotic relationship between mother, placenta, and fetus allowing fetal tolerance and growth^[@bibr79-1756286420936166],[@bibr94-1756286420936166]^                                 Preparation for labor and delivery by induction of uterine contractions, delivery of the infant, and placental separation^[@bibr79-1756286420936166]^

  Direction of immune changes   Pro-inflammatory milieu^[@bibr79-1756286420936166]^                                                                                                                                                                                  Anti-inflammatory milieu with Th2 deviation based on several studies investigating the immunology of pregnancy during this period^[@bibr79-1756286420936166]^                         Pro-inflammatory milieu^[@bibr79-1756286420936166],[@bibr89-1756286420936166]^

  Immune mechanisms             u-NK (70%): weakly cytotoxic unlike peripheral NK; source of cytokines, MMPs and angiogenetic factors.\                                                                                                                              MP, M2-phenotype promotes tissue renewal and placental growth.\                                                                                                                       Activation of inflammation NF-kappa B pathway signaling such as:^[@bibr79-1756286420936166],[@bibr98-1756286420936166]^\
                                MP (20%) and u-NK are involved in vascular and tissue remodeling, angiogenesis, trophoblast invasion and cytokine production. MP digest apoptotic cells secondary to remodeling.\                                                    u-NK interacts with MP-M2 phenotype and generated Tregs.\                                                                                                                             - MP-M1 polarization\
                                T cells (10--20%): 2/3 CD8+ and 1/3 CD4+.\                                                                                                                                                                                           Tregs expand early in pregnancy and promote tolerance to paternal antigens.\                                                                                                          - Production of inflammatory cytokines, chemokines and adhesion molecules\
                                - Exact function yet to be defined\                                                                                                                                                                                                  Th17 cells are present on maternal-fetal interface and prevent from infections.\                                                                                                      - Regulation of cell proliferation, apoptosis, morphogenesis and differentiation\
                                - Might regulate trophoblast invasion\                                                                                                                                                                                               Imbalance in Tregs/Th17 ratio results in spontaneous abortion, pre-term birth and pre-eclampsia.^[@bibr77-1756286420936166],[@bibr79-1756286420936166],[@bibr95-1756286420936166]^\   Paucity of information on B cells, despite newer data on the evolving role for B cells in different phases of pregnancy.^[@bibr97-1756286420936166]^
                                u-DC (rare): weak APC; role in early pregnancy unclear but might prime naïve CD4 to become Th2; crucial role in presenting fetal antigens to T cells leading to tolerance.^[@bibr77-1756286420936166],[@bibr95-1756286420936166]^\   Increasing role of B-cells in suppression of pro-inflammatory milieu.^[@bibr97-1756286420936166]^\                                                                                    
                                Paucity of information on B cells, despite newer data on the evolving role for B cells in different phases of pregnancy.^[@bibr96-1756286420936166],[@bibr97-1756286420936166]^                                                      Paucity of information on B cells, although newer data on the evolving role for B cells in different phases of pregnancy.^[@bibr96-1756286420936166],[@bibr97-1756286420936166]^      

  Impact on MS                  Pro-inflammatory milieu potentially increases risk of post-abortion ARR and gadolinium enhancing lesion accumulation in case of early pregnancy termination.^[@bibr99-1756286420936166]^                                             M2 polarization and Tregs expansion may be associated with the reduction of ARR in full term pregnancies.^5,[@bibr100-1756286420936166],[@bibr101-1756286420936166]^                  Activation of NF-kappa B pathway pre-delivery may contribute to risk of postpartum MS rebound disease activity.^[@bibr102-1756286420936166]^
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

APC, antigen presenting cells; ARR, annualized relapse rate; B cell, B lymphocyte; CD4 T lymphocytes, helper and regulatory type; CD8 T lymphocytes, cytotoxic type; GA, gestational age; MMP, matrix metalloproteinase; MP, macrophage; NF, nuclear factor; Tregs regulatory T lymphocytes; u-DC, uterine dendritic cells; u-NK, uterine natural killer cells.

Recommendations on planning a pregnancy in MS {#section15-1756286420936166}
=============================================

Pregnancy planning is an important consideration for many women with MS.^[@bibr103-1756286420936166]^ Discussing DMT in the context of pregnancy and breastfeeding considerations is essential. It is generally recommended to establish pre-pregnancy baseline, through a clinical neurology visit and an MRI before pregnancy, and to choose a pregnancy-compatible DMT. Visits during the first and third trimester can be helpful, and, during the latter, breastfeeding and postpartum plans can be confirmed. Recommendations for postpartum management are outlined later in this review.

Ideally, women should aim for a period of disease and treatment stability prior to conception. When women receive maintenance DMT, care should be taken to proactively discuss future plans following conception -- including whether or not to continue DMT during pregnancy and plans around breastfeeding. Such discussions are particularly pertinent in women with more active disease. DMTs with potential teratogenicity or contraindicated in pregnancy should be discontinued and replaced with acceptable alternatives prior to conception, or, in case of unintended pregnancy, changed as soon as able. In addition, the tendency for rebound activity after discontinuation of certain DMTs (fingolimod and natalizumab, as discussed later in the review) should be considered prior to initiating therapy in women with plans for pregnancy in the near future. The use of highly effective therapies without rebound risk, such as depleting antibodies, in women with more active disease prior to pregnancy may be preferable, as these may enable a balance between disease control and low potential exposure and risk to the fetus. In women with less active disease, continuing injectable therapies until conception, or even through pregnancy, appears safe, and may offer a favorable risk--benefit ratio.^[@bibr104-1756286420936166]^ Key recommendations are included in [Box 1](#table1-1756286420936166){ref-type="table"}.

###### 

Key expert opinion recommendations for women planning pregnancy and postpartum.

![](10.1177_1756286420936166-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Planning prior to pregnancy***\
  • Preconception counselling should be provided to all women with MS of childbearing age from the time of initial diagnosis and DMT discussion.\
  • Take an individualized approach to pregnancy timing, incorporating the need to minimize MS activity with a suitable DMT where required, along with obstetric factors such as maternal age.\
  • Pregnancy planning involves deciding whether to stop or continue the current DMT. Washout periods differ between DMTs (see [Table 3](#table4-1756286420936166){ref-type="table"}).\
  ○ Injectables (glatiramer acetate, interferon-β) can be safely continued to conception and stopped upon a positive pregnancy test, and could be considered to continue throughout pregnancy after discussion of risks and benefits.\
  ○ Oral DMTs should not be continued during pregnancy, with varying washout depending on the DMT, as outlined in [Table 3](#table4-1756286420936166){ref-type="table"}.\
  ○ Cell-depleting DMTs can be given before pregnancy to women with active MS with timing before conception to limit fetal exposure while providing longer-lasting benefit on disease activity (see [Table 3](#table4-1756286420936166){ref-type="table"}).\
  ○ Special consideration should be made for DMTs with risk of disease reactivation upon discontinuation (e.g., fingolimod, natalizumab), and one may transition to a cell-depleting DMT before pregnancy, or natalizumab may be continued every 8 weeks until approximately 34 weeks gestation to prevent rebound, with evaluation for neonatal risks.\
  • If anticipating prolonged periods of attempted conception and not on an injectable DMT or natalizumab, use of B-cell depleting therapies can be considered in women at higher risk of relapse, with an appropriate time before conception is attempted after each infusion.\
  ***During pregnancy and postpartum***\
  • In the case of unintended pregnancy on a DMT not suitable for use in pregnancy (see [Table 3](#table4-1756286420936166){ref-type="table"}), the DMT should be stopped and an organ screening ultrasound considered, with the accelerated elimination protocol administered for teriflunomide. Caution should be taken if stopping a DMT with risk of rebound.\
  • Many women could consider stopping DMT during pregnancy, although this should be discussed according to individual risks and benefits.\
  • A visit during the third trimester of pregnancy is recommended to plan for the postpartum period.\
  ○ Most women should be encouraged to breastfeed, exclusively, if possible.\
  ○ Women with active MS could consider use of certain DMTs, such as injectable or monoclonal antibody therapies, while breastfeeding (see [Table 4](#table5-1756286420936166){ref-type="table"}).\
  ○ If not breastfeeding, DMT should be resumed within 2--4 weeks postpartum.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adequate vitamin D supplementation prior to conception and during pregnancy (up to 4000 IU/day) is important.^[@bibr105-1756286420936166]^ Timely commencement of folate-containing pre-natal vitamins, avoidance of active or passive smoking, pelvic floor exercises, and proactive diagnosis and treatment of urinary tract infections (UTIs) are also important. UTIs are associated with both worsening of MS symptoms and adverse pregnancy outcomes, and are of particular concern in this patient group.^[@bibr106-1756286420936166]^ Routine pre-natal and pregnancy care can be utilized, unless pregnancy is deemed to be high-risk due to specific obstetrical concerns. Women should be counselled about the risk of postpartum depression. Non-pharmacologic management of fatigue, insomnia, spasticity, and other symptoms during and after pregnancy should be pre-emptively discussed. Use of symptomatic therapies with potential fetal risk should be discussed with the neurologist and maternal fetal medicine specialist.

Pregnancy and DMTs {#section16-1756286420936166}
==================

DMT safety before and during pregnancy {#section17-1756286420936166}
--------------------------------------

In the past decade, there has been an enormous increase in disease modifying treatment options in MS. Fortunately, most women with mild disease will remain relapse-free during pregnancy, and treatment can be safely stopped during pregnancy. At least 300 first-trimester pregnancy exposures, and preferably 1000 total exposures, are needed to assess the possible risk and safety of medication use during pregnancy.^[@bibr107-1756286420936166]^ However, rare events may only be captured with even more exposed pregnancies. Injectable therapies (glatiramer acetate and interferon-β) have the most comprehensive safety data available, and they are safe to continue at least up to conception.^[@bibr108-1756286420936166][@bibr109-1756286420936166][@bibr110-1756286420936166][@bibr111-1756286420936166][@bibr112-1756286420936166][@bibr113-1756286420936166][@bibr114-1756286420936166][@bibr115-1756286420936166][@bibr116-1756286420936166][@bibr117-1756286420936166][@bibr118-1756286420936166][@bibr119-1756286420936166][@bibr120-1756286420936166][@bibr121-1756286420936166]--[@bibr122-1756286420936166]^ Many women stop treatment when they become aware of their pregnancy, most commonly during the first trimester. Therefore, very few data on entire pregnancy exposure exist, with the most data available for glatiramer acetate ([Table 3](#table4-1756286420936166){ref-type="table"}).^[@bibr123-1756286420936166]^

###### 

DMT use in pregnancy and recommendations.

![](10.1177_1756286420936166-table4)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  DMT                                                                                                                                                       Animal data                                                                                                                                                                                         First trimester exposure                                                                                                                                                                                                                                 Exposure throughout pregnancy                                                                                                                                                                                                                                                           Recommendation[\*](#table-fn3-1756286420936166){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Injectables**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Glatiramer acetate^[@bibr124-1756286420936166]^                                                                                                           No embryolethality or teratogenic effects seen^[@bibr124-1756286420936166]^                                                                                                                         No increased risk for SA or CA\                                                                                                                                                                                                                          Limited data shows no increased risk of adverse pregnancy outcomes in *n* \< 250^[@bibr110-1756286420936166],[@bibr113-1756286420936166],[@bibr115-1756286420936166],[@bibr116-1756286420936166],[@bibr120-1756286420936166],[@bibr121-1756286420936166],[@bibr123-1756286420936166]^   - Can be safely continued until positive pregnancy test\
                                                                                                                                                                                                                                                                                                                                                                *n* \> 2500^108--[@bibr120-1756286420936166]^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    - Active approach: continue during pregnancy

  Interferon-β^[@bibr125-1756286420936166][@bibr126-1756286420936166][@bibr127-1756286420936166][@bibr128-1756286420936166]--[@bibr129-1756286420936166]^   Abortifacient effects seen at very high doses\                                                                                                                                                      No increased risk for SA or CA in *n* = 1550^108--[@bibr110-1756286420936166],[@bibr113-1756286420936166],[@bibr115-1756286420936166],[@bibr118-1756286420936166][@bibr119-1756286420936166]--[@bibr120-1756286420936166],[@bibr122-1756286420936166]^   No increased risk of adverse pregnancy outcomes in *n* \< 100^[@bibr113-1756286420936166],[@bibr120-1756286420936166][@bibr121-1756286420936166]--[@bibr122-1756286420936166]^                                                                                                          - Can be safely continued until positive pregnancy test\
                                                                                                                                                            No teratogenic effects or effects on fetal development^[@bibr125-1756286420936166][@bibr126-1756286420936166][@bibr127-1756286420936166][@bibr128-1756286420936166]--[@bibr129-1756286420936166]^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    - Active approach: continue during pregnancy

  **Oral**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Dimethyl fumarate^[@bibr130-1756286420936166],[@bibr131-1756286420936166]^                                                                                No embryolethality\                                                                                                                                                                                 Risk of SA and CA not elevated to date\                                                                                                                                                                                                                  Single cases, so risk unclear                                                                                                                                                                                                                                                           - Stop with contraception or with positive pregnancy test\
                                                                                                                                                            No teratogenicity\                                                                                                                                                                                  *n* = 263, 214 known pregnancy outcomes\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         - In case of accidental exposure during pregnancy: stop\
                                                                                                                                                            At very high dose: low birth weight, delayed ossification and SA                                                                                                                                    Risk of SA: 16/214 (7%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         - EMA: may be used during pregnancy only if the potential benefit justifies potential risk to the fetus
                                                                                                                                                                                                                                                                                                                                                                Risk of CA: 7/214 (4%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                Hellwig ECTRIMS 2019^132^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Diroximel fumarate^[@bibr133-1756286420936166]^                                                                                                           Embryolethality in one species (rabbit) and teratogenicity in one species (rabbit) At very high dose: low birth weight, skeletal variation                                                          Risk of SA and CA still unknown but likely similar to dimethyl fumarate                                                                                                                                                                                  --                                                                                                                                                                                                                                                                                      - Stop with contraception or with positive pregnancy test\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - In case of accidental exposure during pregnancy: stop

  Fingolimod^[@bibr134-1756286420936166],[@bibr135-1756286420936166]^                                                                                       Embryolethality in one species (rabbit) and teratogenicity in one species (rat)                                                                                                                     2-Fold increased risk of major congenital malformations (congenital heart disease, renal and musculoskeletal abnormalities) according to a registry\                                                                                                     \-                                                                                                                                                                                                                                                                                      - EMA: contraindicated without effective contraception and during pregnancy\
                                                                                                                                                                                                                                                                                                                                                                Registry with n = 113 live births with seven major malformations (6.2%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                         - FDA: use effective contraception and avoid pregnancy during and for 2 months after stopping\
                                                                                                                                                                                                                                                                                                                                                                \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                - Stop 2 months before conception and discuss bridging with another DMT\
                                                                                                                                                                                                                                                                                                                                                                Novartis safety database: 3.7% (25/678)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         - In case of accidental exposure during pregnancy: stop and recommend organ screening ultrasound
                                                                                                                                                                                                                                                                                                                                                                Pregnancy outcomes intensive monitoring (PRIM) program: 2% (8/393)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                Hellwig ECTRIMS 2019^136^\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                **EMA alert in September 2019**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Siponimod^[@bibr137-1756286420936166]^                                                                                                                    Embryolethality in one species (rabbit) and teratogenicity in one species (rat)                                                                                                                     Risk of CA still unknown, but likely similar to fingolimod                                                                                                                                                                                               --                                                                                                                                                                                                                                                                                      - FDA: use effective contraception and avoid pregnancy during and for 10 days after stopping\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - Stop 10 days before conception\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - In case of accidental exposure during pregnancy: stop and recommend organ screening ultrasound

  Cladribine^[@bibr138-1756286420936166],[@bibr139-1756286420936166]^                                                                                       Embryolethality in one species (mice) and teratogenicity in two species (rabbit and mice)                                                                                                           Risk of CA unknown, but report of 16 pregnancies within 6 months of cladribine (10 elective terminations; 3 healthy newborns; 2 SA; 1 ectopic) Galazka ECTRIMS 2017^140^                                                                                 --                                                                                                                                                                                                                                                                                      - Pregnancy safe 6 months after the last administration\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - Risk of interaction between cladribine and oral contraception: women must also use mechanical contraception during the days of treatment and at least 4 weeks after the last dose

  Teriflunomide^[@bibr141-1756286420936166],[@bibr142-1756286420936166]^                                                                                    Embryolethality and teratogenicity in two species (rabbit and rat)                                                                                                                                  No increased risk of CA *n* = 437, 222 known pregnancy outcomes (risk of major malformation: 3.6% (1/28) in clinical trials, 0% (0/51) in post-marketing data)^[@bibr143-1756286420936166]^                                                              --                                                                                                                                                                                                                                                                                      - FDA/EMA: contraindicated in pregnant women or women of reproductive potential not using effective contraception\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - Stop before conception with accelerated elimination procedure (serum level \<0.02 mg/l twice, 2 weeks apart)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - In case of accidental exposure during pregnancy: stop, accelerated elimination procedure and recommend organ screening ultrasound

  **Infusion**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Natalizumab^[@bibr144-1756286420936166],[@bibr145-1756286420936166]^                                                                                      No abortifacient or teratogenic effects, but immunological and hematologic effects^[@bibr146-1756286420936166]^                                                                                     Risk for SA and CA most likely not elevated^[@bibr147-1756286420936166]^\                                                                                                                                                                                Hematologic abnormalities^[@bibr150-1756286420936166],[@bibr151-1756286420936166]^\                                                                                                                                                                                                     - Case-by-case decision\
                                                                                                                                                                                                                                                                                                                                                                *n* = 369, 355 known outcomes with 9.0% SA and 5.05% CA^[@bibr148-1756286420936166]^\                                                                                                                                                                    Possible increased risk of malformation (4/31) and anemia (5/31)^[@bibr152-1756286420936166]^                                                                                                                                                                                           - Consider switch to depleting agents\
                                                                                                                                                                                                                                                                                                                                                                *n* = 92, 17.4% SA and 3.7% CA^[@bibr147-1756286420936166]^\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     - Semi-active: stop with positive pregnancy test but risk of rebound relapse\
                                                                                                                                                                                                                                                                                                                                                                *n* = 98, 17.3% SA and 5.2% CA^[@bibr149-1756286420936166]^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      - Active: maintain during pregnancy (can give every 8 weeks and last dose at approximately 34 weeks),^[@bibr76-1756286420936166]^ evaluate neonate for hematological abnormalities

  Rituximab^[@bibr153-1756286420936166],[@bibr154-1756286420936166]^                                                                                        Transient peripheral B cell depletion^[@bibr155-1756286420936166]^                                                                                                                                  Reduced B cell count in newborns^[@bibr156-1756286420936166],[@bibr157-1756286420936166]^ if treated during pregnancy\                                                                                                                                   Reduced B cell count in newborns^[@bibr156-1756286420936166],[@bibr157-1756286420936166]^                                                                                                                                                                                               - Attempt conception 1--3 months after the last dose^[@bibr158-1756286420936166]^\
                                                                                                                                                                                                                                                                                                                                                                Risk for SA and CA likely not elevated *n* = 102 with 12% SA and 4.5% CA or medical conditions^[@bibr157-1756286420936166]^                                                                                                                                                                                                                                                                                                                                                                                                                      - Discontinue in case of pregnancy\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - Re-dose if not pregnant after 6--9 months\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - Pregnancy test before each infusion

  Ocrelizumab^[@bibr159-1756286420936166],[@bibr160-1756286420936166]^                                                                                      B cell depletion observed\                                                                                                                                                                          Risk for SA likely not elevated *n* = 118, 54 known outcomes with 7.4% (4/54) SA and 3% (1/32 at risk) stillbirth^[@bibr161-1756286420936166],[@bibr162-1756286420936166]^                                                                               Limited^[@bibr161-1756286420936166],[@bibr162-1756286420936166]^                                                                                                                                                                                                                        - Attempt conception 1--3 months after the last dose\
                                                                                                                                                            In monkeys, increased perinatal mortality, renal, bone marrow and testicular toxicity^[@bibr159-1756286420936166],[@bibr160-1756286420936166]^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       - Discontinue in case of pregnancy\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - Re-dose if not pregnant after 6--9 months\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - Pregnancy test before each infusion

  Alemtuzumab^[@bibr163-1756286420936166],[@bibr164-1756286420936166]^                                                                                      Embryolethal when administered during organogenesis^[@bibr163-1756286420936166],[@bibr164-1756286420936166]^ and decreased B and T lymphocyte populations                                           Slightly elevated risk for SA cannot be excluded *n* = 193, 167 known outcomes with 22% SA, 0% CA, 0.6% stillbirth^[@bibr165-1756286420936166]^                                                                                                          --                                                                                                                                                                                                                                                                                      - Conception 4 months after last infusion may be attempted\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - Pregnancy test prior to each course\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 - Monitor thyroid function and antithyroid antibodies (placental transfer of anti-thyrotropin receptor antibodies resulting in neonatal Graves' disease observed)^[@bibr163-1756286420936166]^
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Some recommendations for timing of DMT use around pregnancy are off-label and represent expert opinion based on available data.

CA, congenital abnormality; DMT, disease-modifying therapy; EMA, European Medicines Agency; FDA, Food and Drug Administration; SA, spontaneous abortion.

Immunological changes during pregnancy may not be sufficient to protect women with active disease from relapses or rebound, especially after withdrawal from fingolimod or natalizumab.^[@bibr166-1756286420936166][@bibr167-1756286420936166]--[@bibr168-1756286420936166]^ The continuation of natalizumab, or bridging with the use of depleting antibodies or cladribine prior to conception should be considered in these patients. Oral DMTs should not be continued in pregnancy, whereas depleting antibody therapies can potentially be used in women with active MS, ideally prior to pregnancy, but with biological effects that may persist after drug elimination.

More data are necessary to fully address this challenging clinical topic, especially for women with more aggressive MS who wish to have children. Current knowledge of the safety of MS DMTs during pregnancy is outlined in [Table 3](#table4-1756286420936166){ref-type="table"}.

DMT safety in breastfeeding {#section18-1756286420936166}
---------------------------

Although breastfeeding may reduce risk,^[@bibr169-1756286420936166]^ individuals at high risk for postpartum relapse may require additional strategies to decrease relapse risk, such as restarting DMT. Interferon-beta preparations were recently approved by the European Medicines Association (EMA) for use while breastfeeding,^[@bibr125-1756286420936166]^ but the US Food and Drug Administration (FDA) has not done so. Mothers have historically faced a choice about whether to breastfeed -- which has significant benefits to both the mother and infant -- or treat their MS.^[@bibr170-1756286420936166]^ However, some DMTs are unlikely to pass in relevant or harmful quantifies to breastmilk, underscoring the importance of designing studies to support the ability for women to both safely breastfeed while treating their disease.

Transfer of drugs to breastmilk depends on several factors, including molecular weight, protein binding, lipid solubility, volume of distribution, and transport mechanisms, as well as the stage of breastmilk, with less transfer into mature milk than colostrum.^[@bibr171-1756286420936166]^ Lactation studies are required to determine breastmilk transfer, and a commonly used measure is the relative infant dose (RID), which represents the percent of the weight-adjusted maternal dose consumed in breastmilk over 24 h. RID of \<10% is generally considered acceptable for breastfeeding, although the toxicity of each drug should be considered.^[@bibr172-1756286420936166]^ Based on these considerations, an overview of data on excretion of DMTs to breastmilk, and recommendations for DMT use while breastfeeding are listed in [Table 4](#table5-1756286420936166){ref-type="table"}.

###### 

DMT use during lactation and recommendations.

![](10.1177_1756286420936166-table5)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  DMT                                                                                                       Animal data excretion into breastmilk                                                                                                                                                                                                                                           Human data excretion into breastmilk                                                                                                                     Relative infant dose in human                                                                                                                                    Recommendation[\*](#table-fn5-1756286420936166){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  **Injectables**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Glatiramer acetate^[@bibr121-1756286420936166],[@bibr124-1756286420936166],[@bibr173-1756286420936166]^   Limited data                                                                                                                                                                                                                                                                    Unknown, but low likelihood due to large MW (4700--13,000 Da) but broken rapidly into its amino acid components                                          --                                                                                                                                                               Probably compatible with breastfeeding

  Interferon-β^[@bibr121-1756286420936166],[@bibr125-1756286420936166],[@bibr173-1756286420936166]^         Limited data                                                                                                                                                                                                                                                                    Negligible in 6 women^[@bibr174-1756286420936166]^\                                                                                                      0.006%^[@bibr174-1756286420936166]^                                                                                                                              Compatible with breastfeeding\
                                                                                                                                                                                                                                                                                                                                                                                            Low likelihood due to large MW (22,500 Da)                                                                                                                                                                                                                                                                                EMA: IFN-beta can be used while breastfeeding^[@bibr125-1756286420936166]^

  **Oral**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Dimethyl fumarate^[@bibr130-1756286420936166],[@bibr131-1756286420936166]^                                Limited data                                                                                                                                                                                                                                                                    Unknown, but likely due to low MW (129 Da) of active metabolite (MMF), although rapid metabolism and high volume of distribution may decrease transfer   --                                                                                                                                                               Breastfeeding not recommended

  Diroximel fumarate^[@bibr133-1756286420936166]^                                                           Limited data                                                                                                                                                                                                                                                                    Unknown, but likely due to low MW (129 Da) of active metabolite (MMF), although rapid metabolism and high volume of distribution may decrease transfer   --                                                                                                                                                               Breastfeeding not recommended

  Fingolimod^[@bibr134-1756286420936166],[@bibr135-1756286420936166]^                                       Excreted in milk of treated rats (2--3-fold higher in milk than maternal plasma)                                                                                                                                                                                                Unknown, but likely due to low MW (344 Da) and long t~1/2~ although high protein binding could decrease transfer                                         --                                                                                                                                                               Breastfeeding not recommended

  Siponimod^[@bibr137-1756286420936166]^                                                                    Excreted in milk of treated rats                                                                                                                                                                                                                                                Unknown, but likely due to long t~1/2~ although moderate MW (1149 Da) and high protein binding could decrease transfer                                   --                                                                                                                                                               Breastfeeding not recommended

  Cladribine^[@bibr138-1756286420936166],[@bibr139-1756286420936166]^                                       Limited data                                                                                                                                                                                                                                                                    Unknown, but likely due to low MW (286 Da) and low protein binding, although high volume of distribution may decrease transfer                           --                                                                                                                                                               Breastfeeding not recommended (contraindicated - FDA for 10 days and EMA 7 days after last dose)

  Teriflunomide^[@bibr141-1756286420936166],[@bibr142-1756286420936166]^                                    Detected in rat milk after single oral dose                                                                                                                                                                                                                                     Unknown, but likely due to low MW (270 Da) and long t~1/2~ although high protein binding could decrease transfer                                         --                                                                                                                                                               Breastfeeding not recommended (contraindicated by EMA and not recommended by FDA)

  **Infusion**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Natalizumab^[@bibr144-1756286420936166],[@bibr145-1756286420936166]^                                      Low levels of natalizumab in breastmilk in cynomolgus monkeys treated until parturition^[@bibr145-1756286420936166]^                                                                                                                                                            Low in seven women^[@bibr175-1756286420936166][@bibr176-1756286420936166]--[@bibr177-1756286420936166]^                                                  5.30% (based on peak concentration) and 1.74% (based on average concentration),^[@bibr175-1756286420936166]^ but cumulative effects of monthly dosing possible   Probably compatible with breastfeeding but further study needed

  Rituximab^[@bibr153-1756286420936166],[@bibr154-1756286420936166]^                                        Detected in cynomolgus monkey milk^[@bibr153-1756286420936166],[@bibr154-1756286420936166]^                                                                                                                                                                                     Low in nine women^[@bibr178-1756286420936166]^                                                                                                           0.08% (range 0.06--0.10)^[@bibr178-1756286420936166]^                                                                                                            Probably compatible with breastfeeding

  Ocrelizumab^[@bibr159-1756286420936166],[@bibr160-1756286420936166]^                                      Detected in milk of treated monkeys,^[@bibr159-1756286420936166]^ with levels about 0.2% of steady state trough serum levels during lactation^[@bibr160-1756286420936166]^                                                                                                      Unknown, but likely low given large MW and limited known IgG1 transfer into breastmilk                                                                   --                                                                                                                                                               Probably compatible with breastfeeding

  Alemtuzumab^[@bibr163-1756286420936166],[@bibr164-1756286420936166]^                                      Detected in milk and offspring of lactating mice treated postpartum; ^[@bibr163-1756286420936166],[@bibr164-1756286420936166]^ Serum levels similar in lactating mice and offspring, and associated with decrease in offspring lymphocyte counts^[@bibr163-1756286420936166]^   Unknown, but likely to be low given large MW and limited known IgG1 transfer into breastmilk                                                             --                                                                                                                                                               Probably compatible with breastfeeding\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      EMA: breastfeeding 4 months after the last dose safe (specific timing not advised by FDA)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Some recommendations for DMT use while breastfeeding are off-label and represent expert opinion based on available data.

DMT, disease-modifying therapy; EMA, European Medicines Agency; FDA, Food and Drug Administration; MMF, monomethyl fumarate; MW, molecular weight; t~1/2~, half life.

While additional study of DMT use during lactation is required, when deciding whether to breastfeed while using DMTs, patients and clinicians should consider the risk of postpartum relapse balanced with potential adverse effects to the infant. In patients with high risk of postpartum disease activity, the benefits of breastfeeding despite DMT may outweigh risks for the injectable and monoclonal antibody therapies, while breastfeeding is not suggested while on oral DMTs. A recent review similarly suggested breastfeeding while on monoclonal antibody therapies can be considered in neuromyelitis optica spectrum disorders.^[@bibr179-1756286420936166]^ It is important to note that data are lacking regarding the long-term immunological and infectious profile of children of women with MS exposed to DMTs in breastmilk.

Obstetric management {#section19-1756286420936166}
====================

Management of women with MS during labor and delivery is relevant to obstetricians, neurologists, anesthesiologists, and patients. Concern regarding associations between spinal anesthesia and MS relapses emerged almost 70 years ago.^[@bibr180-1756286420936166]^ Since then, prospective studies and a meta-analysis have demonstrated the safety of spinal anaesthesia in MS.^[@bibr5-1756286420936166],[@bibr81-1756286420936166],[@bibr181-1756286420936166],[@bibr182-1756286420936166]^ The American Society of Regional Anesthesia and Pain Medicine states in its 2015 guidelines that epidural anesthesia is considered safer than spinal anesthesia because it does not deposit local anesthetic directly adjacent to the CNS.^[@bibr183-1756286420936166]^ However, choice of analgesia in labor is best left to discretion of the obstetrician and anesthesiologist in discussion with the woman.

Disease-related factors such as fatigue, lower limb weakness, and spasticity need to be considered when developing a birth plan, and should be discussed during prenatal care.^[@bibr184-1756286420936166]^ As commonly used symptomatic treatments such as baclofen and dalfampridine are contraindicated in pregnancy, a greater emphasis on physical therapy may be needed to manage symptoms. Clinicians' apprehension may lead to an increase in cesarean section or instrumental interventions during delivery. However, reports of increased cesarean section deliveries in women with MS may be confounded by cultural and geographical influences on cesarean rates.^[@bibr185-1756286420936166]^ In many countries, obstetrical care during labor is managed by midwives, and it is important that education on management of women with MS during labor extends to all involved medical professionals.

A systematic review and meta-analysis of women with MS and their pregnancies concluded that women with MS do not have a significantly increased risk of obstetrical or neonatal complications such as prematurity or neonatal death.^[@bibr186-1756286420936166]^ Management of women with MS during labor and delivery is therefore generally left to the discretion of the obstetrician (or midwife) and anesthesiologist. Clear communication from the neurologist to outline the disease state of the woman with MS, any relevant functional impairments, as well as optimization of MS-related symptom management, remains an important part of holistic care during pregnancy and should be a key focus of the neurologist's involvement.

Pregnancy and disease course: short-term outcomes and postpartum relapse risk {#section20-1756286420936166}
=============================================================================

In the early 20th century, pregnancy was believed to promote poorer outcomes for women with MS, and was discouraged. This perception changed with the landmark Pregnancy in Multiple Sclerosis (PRIMS) study, published in 1998.^[@bibr5-1756286420936166]^ This prospective multicenter study, including data from 269 pregnancies across 12 European countries, revealed a \~70% decrease in relapse rate in the third trimester, relative to the 12 months pre-conception, and a postpartum relapse rate increase of \~170%. Subsequently, Vukusic showed that following the initial postpartum increase in relapses,^[@bibr81-1756286420936166]^ ARR returned to pre-pregnancy levels. The findings of the seminal PRIMS,^[@bibr5-1756286420936166]^ and its extension,^[@bibr81-1756286420936166]^ have been replicated across numerous cohorts in subsequent decades,^[@bibr39-1756286420936166],[@bibr187-1756286420936166][@bibr188-1756286420936166][@bibr189-1756286420936166][@bibr190-1756286420936166]--[@bibr191-1756286420936166]^ and confirmed in a meta-analysis.^[@bibr186-1756286420936166]^ The seemingly high postpartum relapse rate is driven by a minority of women. Various studies estimate that relapses occur in 14--31% within the first 3 months postpartum.^[@bibr5-1756286420936166],[@bibr190-1756286420936166],[@bibr191-1756286420936166]^ In women with mild MS, the trend for postpartum relapse has generally diminished in the two decades following the PRIMS study.^[@bibr192-1756286420936166]^ A contemporary population-based cohort of women with MS and CIS did not find rebound disease activity postpartum, attributed to inclusion of women with milder disease and high rates of exclusive breastfeeding.^[@bibr192-1756286420936166]^ However, recent studies have demonstrated that women treated with highly effective therapies, specifically fingolimod and natalizumab, are at increased risk of rebound relapse activity in pregnancy and the postpartum period once therapy is withdrawn, with rebound relapses associated with longer duration of wash-out.^[@bibr166-1756286420936166][@bibr167-1756286420936166]--[@bibr168-1756286420936166],[@bibr187-1756286420936166],[@bibr193-1756286420936166][@bibr194-1756286420936166][@bibr195-1756286420936166]--[@bibr196-1756286420936166]^

In terms of short-term MS outcomes beyond relapse activity, the PRIMS study reported a mean increase of 0.9 points on the Kurtzke disability scale over a 24-month period, without an apparent acceleration in disability worsening.^[@bibr5-1756286420936166],[@bibr81-1756286420936166]^ Sixteen years later, a study of 338 women from an Italian multicenter cohort demonstrated that short-term increases in disability accrual (6-month confirmed disability progression) postpartum were driven primarily by relapse activity in the year after delivery.^[@bibr197-1756286420936166]^

Postpartum outcomes are not limited to women with live births. A recent Italian multicenter study of 188 abortions (17 elective) in RRMS reported that women were at increased risk of clinical and radiological inflammatory activity in the 12 months post-abortion compared with pre-abortion, and risk of inflammatory activity was higher in those with elective compared with spontaneous abortion.^[@bibr99-1756286420936166]^ Similarly, a smaller study reported a trend towards increased MS activity after pregnancy loss compared with before.^[@bibr198-1756286420936166]^ The relative risk of inflammatory activity in women who have had abortions relative to women with live births remains unknown.

Various studies have proposed predictors of postpartum relapses,^[@bibr5-1756286420936166],[@bibr81-1756286420936166],[@bibr166-1756286420936166],[@bibr187-1756286420936166],[@bibr189-1756286420936166][@bibr190-1756286420936166]--[@bibr191-1756286420936166],[@bibr196-1756286420936166],[@bibr199-1756286420936166][@bibr200-1756286420936166]--[@bibr201-1756286420936166]^ summarized in [Table 5](#table6-1756286420936166){ref-type="table"}. Beyond withdrawal of highly effective therapies,^[@bibr166-1756286420936166],[@bibr193-1756286420936166]^ these studies have consistently demonstrated that patients with higher relapse activity pre-conception and during pregnancy, as well as EDSS scores of \>2.0 at conception are the key independent predictors of postpartum relapses.^[@bibr81-1756286420936166],[@bibr191-1756286420936166],[@bibr197-1756286420936166]^ Potentially modifiable risk factors of postpartum relapse such as resuming DMT, vitamin D status, diet, smoking, alcohol, and stress have not been adequately studied.^[@bibr202-1756286420936166]^ On the other hand, breastfeeding has received substantial interest, and is discussed in detail in the following section.

###### 

Proposed predictors of postpartum relapses.

![](10.1177_1756286420936166-table6)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protective against postpartum relapse                 Risk factors associated with postpartum relapse                                             No consistent effect on postpartum relapse
  ----------------------------------------------------- ------------------------------------------------------------------------------------------- --------------------------------------------------
  - Pre-conception disease modifying therapy use\       - Higher disease activity pre-conception (preceding 12 months)\                             - Age (neither at the onset of MS or pregnancy)\
  - Lower disease activity pre-conception\              - Higher disease activity during pregnancy\                                                 - Number of prior pregnancies\
  - Early re-initiation of disease modifying therapy\   - Higher disability level at onset of pregnancy\                                            - Infant sex\
  - Potentially breastfeeding, particularly exclusive   - Longer wash out period after discontinuation of high-efficacy disease-modifying therapy   - Cesarean section\
                                                                                                                                                    - Use of epidural anesthesia\
                                                                                                                                                    - Postpartum use of IVIG or IV steroids

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IV, intravenous; IVIG, intravenous immune globulin; MS, multiple sclerosis.

Breastfeeding and postpartum relapses {#section21-1756286420936166}
=====================================

The effect of breastfeeding on postpartum relapse risk has been controversial, with some studies supporting a protective effect,^[@bibr192-1756286420936166],[@bibr200-1756286420936166],[@bibr201-1756286420936166],[@bibr203-1756286420936166],[@bibr204-1756286420936166]^ while others have not.^[@bibr5-1756286420936166],[@bibr119-1756286420936166],[@bibr199-1756286420936166],[@bibr205-1756286420936166][@bibr206-1756286420936166][@bibr207-1756286420936166][@bibr208-1756286420936166][@bibr209-1756286420936166][@bibr210-1756286420936166][@bibr211-1756286420936166]--[@bibr212-1756286420936166]^ There is no evidence to suggest a harmful effect of breastfeeding on MS relapse risk, which is important given the many benefits of breastfeeding to the infant and mother.^[@bibr170-1756286420936166]^ A recent systematic review and meta-analysis included 24 studies evaluating the association between breastfeeding and postpartum MS relapses, of which 16 had data available to pool.^[@bibr169-1756286420936166]^ Overall, breastfeeding was associated with 37% lower odds of postpartum relapse compared with nonbreastfeeding. This association was stronger in studies of exclusive breastfeeding (no regular formula supplementation for ⩾2 months) with 48% lower odds of postpartum relapse, compared with 32% lower odds in studies of nonexclusive breastfeeding. One study reported that women who partially breastfed had similar relapse risk to those who did not breastfeed,^[@bibr201-1756286420936166]^ supporting benefit primarily of exclusive breastfeeding. Confounding and other sources of bias remain a concern given the observational design of these studies, although pooling four well-designed studies was supportive of a protective effect with 43% lower rate of postpartum relapse in breastfeeding compared with nonbreastfeeding groups.^[@bibr169-1756286420936166]^ The potentially protective effect of breastfeeding may be due to breastfeeding-associated hormonal changes including suppression of pulsatile release of GnRH and LH, as well as high prolactin.^[@bibr213-1756286420936166]^

Management of MS during the postpartum period should be individualized based on postpartum relapse risk. In those with particularly high risk of postpartum relapse, breastfeeding may be deferred to resume MS therapies. However, the majority of women with MS should be encouraged to breastfeed, and some therapies may be safe to use while breastfeeding. A better understanding of additional strategies to prevent postpartum relapses is urgently needed, including better understanding of the safety of breastfeeding during treatment with DMTs, to allow both the benefit of breastfeeding and treatment of MS.

Postpartum management {#section22-1756286420936166}
=====================

In the postpartum period, there are three treatment goals: to prevent inflammatory activity, to provide holistic care, and to optimize psychosocial functioning. Whenever possible, anticipatory guidance should be initiated prior to delivery to minimize delays in care. Care should be in collaboration with the mother, other family members, and, when necessary (e.g., concerns about maternal medications in breastmilk), other healthcare providers.

To prevent inflammatory activity, individualized decisions should be made regarding when to resume DMT, choice of DMT, breastfeeding plans, and use of bridge therapies if indicated. A surveillance MRI 4--6 weeks postpartum may assist in monitoring for subclinical disease activity, particularly in women who delay early DMT initiation. Most women with MS should be encouraged to breastfeed, but those who cannot, or do not wish to, breastfeed should be advised to resume DMT within 2--4 weeks postpartum. For those breastfeeding with higher risk of relapse, certain DMTs could be considered while breastfeeding, as outlined elsewhere in this review.

The second goal is to comprehensively evaluate the woman's function. There are limited data to guide care. In our clinical experience, monitoring includes evaluating and treating the following functions and when warranted multidisciplinary referrals (e.g., psychologist, psychiatrist, physical therapist, pelvic floor therapist, and/or urologist).

-   Screening for peripartum depression (PPD), anxiety or milder "baby blues." PPD is present in 7--19% of all women in the peripartum period (final weeks of pregnancy through 1 year postpartum), and a major risk factor is prior history of depression.^[@bibr214-1756286420936166][@bibr215-1756286420936166]--[@bibr216-1756286420936166]^ For the general population, screening with the Edinburgh Postnatal Depression Scale with a cutoff of 13 is acceptable, and "screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up."^[@bibr217-1756286420936166]^ PPD in MS is under-explored.^[@bibr218-1756286420936166]^

-   Fatigue may worsen postpartum as a result of sleep disruption (newborn needs, mood, or bladder changes) or hormonal changes. Contributing factors should be assessed prior to initiation of medications.

-   Strength and gait optimization including screening for weakness, loss of balance, or cardiopulmonary deconditioning.

-   Evaluation of bladder and bowel function, which could be disrupted from neurogenic and/or obstetrical causes but is understudied,^[@bibr219-1756286420936166],[@bibr220-1756286420936166]^ and consideration of pre-emptive referral to pelvic floor physical therapy.

-   Screening for endocrine changes may include vitamin D level,^[@bibr211-1756286420936166],[@bibr221-1756286420936166]^ which in some, but not all, studies has been associated with inflammatory activity in MS,^[@bibr211-1756286420936166],[@bibr222-1756286420936166]^ as well as thyroid function.^[@bibr223-1756286420936166]^

The third goal is to optimize the patient's psychosocial functioning, minimizing as possible disruption caused by postpartum recovery and care of the newborn, and optimizing support available to her. This support may include assistance (from the partner, other family members or a professional) with management of the newborn to enable periods of rest. A social worker may provide advice regarding short-term disability leave and/or financial resources when needed.

Pregnancy and disease course: long-term outcomes {#section23-1756286420936166}
================================================

Despite the potential increased relapse risk postpartum, the majority of individuals do not experience relapses in the postpartum period, and pregnancy does not appear to alter long-term relapse rate or disease progression.^[@bibr5-1756286420936166],[@bibr81-1756286420936166],[@bibr166-1756286420936166]^ However, the impact of pregnancy on long-term outcomes remains less clear. Studies up to the mid-2010s demonstrated either a slower rate of disability progression in women becoming pregnant after MS onset,^[@bibr38-1756286420936166],[@bibr71-1756286420936166],[@bibr224-1756286420936166][@bibr225-1756286420936166][@bibr226-1756286420936166]--[@bibr227-1756286420936166]^ or failed to demonstrate an association between pregnancy and long-term disability.^[@bibr228-1756286420936166][@bibr229-1756286420936166]--[@bibr230-1756286420936166]^ One notable exception found weak evidence for increased risk of converting to SPMS over 10-years in a parous cohort (on injectable or no DMT).^[@bibr231-1756286420936166]^

More recently, a protective effect of pregnancy on long-term outcomes was reported in a large real-world cohort (MSBase). Females with at least one pregnancy had lower EDSS scores over 10 years, after adjustment for relapse rate, therapy use, and other covariates.^[@bibr232-1756286420936166]^ Interestingly, when comparing proportion of time spent pregnant with proportion of time on first-line therapy, the protective effect of pregnancy was greater. While the possibility of reverse causality (women with milder disease more likely to attempt pregnancy) cannot be excluded, this is challenged by the fact that approximately half of pregnancies were conceived while on therapy. In the Barcelona CIS cohort, pregnancy after CIS was protective against risk of MS, and time to EDSS 3.0 if pregnancy was modelled as a baseline variable. However, these protective effects were lost when pregnancy was analyzed as a time-dependent variable.^[@bibr233-1756286420936166]^ Notably, 32% of this cohort did not fulfill Barkhof criteria, potentially limiting generalizability.

Overall, there is little-to-no evidence that pregnancy has a negative impact on long-term outcomes at the group level, with most studies demonstrating a neutral or protective effect. MS does not preclude parenthood or pregnancy.^[@bibr234-1756286420936166]^ Nonetheless, the effect of pregnancy on disease outcomes, a woman's ability to care for her child, and future financial stress are key concerns of women with MS considering family planning.^[@bibr235-1756286420936166][@bibr236-1756286420936166][@bibr237-1756286420936166]--[@bibr238-1756286420936166]^ Relapses are the greatest independent driver of long-term disability accrual.^[@bibr232-1756286420936166]^ Therefore, careful pregnancy planning and monitoring including appropriate use/withdrawal of DMTs is paramount to ensuring positive long-term outcomes for women with MS.^[@bibr239-1756286420936166],[@bibr240-1756286420936166]^

Further studies are needed to evaluate effects of pregnancy in PPMS, address issues of reverse causality, and understand the long-term impact of pregnancy in heterogeneous cohorts to allow pregnancy planning advice tailored to the individual.

Stigma around family planning {#section24-1756286420936166}
=============================

Stigma means mark of inferiority.^[@bibr241-1756286420936166][@bibr242-1756286420936166]--[@bibr243-1756286420936166]^ People with MS or their partners who want to procreate may be questioned about wishing to have children despite a neurodegenerative condition. They may be judged by their family, society, the healthcare team, and even their partners. Moreover, they may feel guilty and fearful of unforeseen consequences,^[@bibr244-1756286420936166],[@bibr245-1756286420936166]^ even though MS has negligible impact on pregnancy and vice versa.^[@bibr240-1756286420936166]^ They may conceal their desires and their condition,^[@bibr242-1756286420936166],[@bibr246-1756286420936166]^ or discontinue treatment. This fear and stigma may have greater impact on quality of life of prospective parents than the actual disease.^[@bibr240-1756286420936166],[@bibr247-1756286420936166]^

While it is not implied that every couple should procreate, expert support and multidisciplinary guidance could help patients structure their lives and manage their condition, to allow them to have a positive reproductive experience.^[@bibr241-1756286420936166],[@bibr248-1756286420936166]^

Exogenous hormones as a DMT with impact on long-term prognosis of MS {#section25-1756286420936166}
====================================================================

High doses of estrogen seem to be protective by decreasing MS disease activity in the EAE animal model and women during pregnancy.^[@bibr249-1756286420936166]^ Observational studies of potential effects of oral contraceptives and ART are discussed earlier in this review. To solve the inherent limitations of retrospective and observational studies, two randomized-controlled, phase II, clinical trials have assessed the impact of exogenous hormones on disease course.^[@bibr249-1756286420936166],[@bibr250-1756286420936166]^ They suggest that the addition of ethinyl estradiol 40 µg and desogestrel 125 µg to interferon-β-1a,^[@bibr250-1756286420936166]^ and estriol to glatiramer acetate,^[@bibr249-1756286420936166]^ are associated with fewer lesions on brain MRI (26.5% reduction of cumulative number of combined unique active lesions, *p* = 0.04), and lower ARR (0.25 *versus* 0.48, *p* = 0.016 at 12 months), respectively. In addition, both studies showed promising effects of estrogen on cognitive disability as exploratory outcomes. Estriol treatment-induced cognitive improvement was correlated with less cerebral cortex gray matter atrophy,^[@bibr249-1756286420936166]^ which was mapped to sparing of frontal cerebral cortex.^[@bibr251-1756286420936166]^ Further research is needed to understand the effect of exogenous hormones on long-term MS prognosis in women.

Menopause and reproductive aging {#section26-1756286420936166}
================================

Like puberty and pregnancy, perimenopause leads to widespread changes in biology. Changes in the immune and nervous systems, fluctuations in gonadal hormones, and symptoms that overlap with those caused by MS may contribute to changes in clinical phenotype to a progressive disease course over the fifth decade.^[@bibr252-1756286420936166]^ Challenges in understanding the role of perimenopause in MS include distinguishing effects of somatic *versus* reproductive aging and the potential confounding from comorbid illnesses that become more frequent with older age.

Ovarian aging and disease course {#section27-1756286420936166}
--------------------------------

The mean age of onset of secondary progressive MS, characterized by a change from a relapsing remitting phenotype to a continuously progressive form of disease, conspicuously occurs for most women during the perimenopausal period. Several studies have aimed to determine if the menopausal transition affects disease course. Some have reported clinical worsening when patients were asked about their disease perception during menopausal transition,^[@bibr253-1756286420936166][@bibr254-1756286420936166]--[@bibr255-1756286420936166]^ possibly due to the additive effect of menopause and MS overlapping symptoms. On the other hand, others have focused on the search for an inflection point in MS course centered on menopause. Bove *et al.* described an inflection point in EDSS worsening at menopause (difference of 0.076 units; 95% CI 0.010--0.14, *p* = 0.024) in 124 women followed longitudinally (mean follow up 10.4 years).^[@bibr8-1756286420936166]^ This was replicated by Baroncini *et al.*, who also reported a significant annual EDSS increase in the post-menopausal period (3 years) as compared with the pre-menopausal period (3 years) (0.4 ± 0.7 *versus* 0.2 ± 0.6 points, *p* = 0.014) in 108 women.^[@bibr256-1756286420936166]^ In a smaller cohort (*n* = 37), Ladeira *et al.* detected stable EDSS variation across the menopausal transition.^[@bibr6-1756286420936166]^ Ladeira *et al.* and Baroncini *et al.* also reported significant decrease in annual relapse rate after menopause.^[@bibr6-1756286420936166],[@bibr256-1756286420936166]^ On the other hand, Otero *et al.* found that menopause did not influence the risk of disability accumulation when trajectories of EDSS over the complete disease course (from CIS through menopause) were accounted for, and once adjusting for age and disease duration.^[@bibr72-1756286420936166]^

Much of the ovarian aging biology accumulates years before the final menstrual cycle, highlighting a continuum of physiological changes, rather than any abrupt change arising at the final menstrual period that could influence MS course. To study the prolonged period of ovarian decline, Graves *et al.* used AMH as a marker of ovarian function.^[@bibr9-1756286420936166]^ AMH is produced by ovarian follicles, and levels decline exponentially during the peri-menopausal period. Within a 10-year longitudinal cohort, declines in AMH level were associated with clinically and statistically significant increases in disability and gray matter atrophy, even with adjustment for chronological age, BMI, and disease duration.^[@bibr9-1756286420936166]^

Mechanistically, the loss of ovarian estrogen around menopause could potentiate several aging-associated phenomena, including decrease in brain repair mechanisms, decrease in immune activation, and, ultimately, a loss of neuro-homeostasis leading to accelerated neurodegeneration and subsequent disease progression.^[@bibr257-1756286420936166][@bibr258-1756286420936166]--[@bibr259-1756286420936166]^ The subsequent results of these potential changes include increased levels of senescent immune cells and neurons as well as increased CNS atrophy and disability. Notably, cognition is one disability in MS that may be particularly sensitive to loss of estrogens during menopause in light of the well-documented "brain fog" described in otherwise healthy women during natural menopause with aging and surgical menopause not due to aging.^[@bibr260-1756286420936166][@bibr261-1756286420936166][@bibr262-1756286420936166][@bibr263-1756286420936166][@bibr264-1756286420936166]--[@bibr265-1756286420936166]^ However, estrogen may not be the only culprit as there are also substantial changes in androgen production, and it is difficult to tease apart the effects of somatic aging processes that are linked with perimenopause in women.

Symptom management in perimenopause {#section28-1756286420936166}
-----------------------------------

Few studies have addressed management of MS symptoms at menopause. Symptom management and choice of DMT should be tailored to account for fatigue and pseudo-exacerbations triggered by hot flashes, which can become more prominent at menopause.^[@bibr266-1756286420936166],[@bibr267-1756286420936166]^ Co-management with primary or women's health providers may be beneficial. Bladder symptoms may also worsen and urology assessment may be needed.

Prospective, randomized studies on the effect of hormone therapy in patients with MS during menopause are needed, as prior studies reported improved quality of life in post-menopausal women with MS.^[@bibr266-1756286420936166]^ Wellness approaches, attention to co-morbidities, as well as adding a neuroprotective agent may be appropriate when these are substantiated and become available for women living with MS at menopause and beyond.

Female sexual dysfunction in MS {#section29-1756286420936166}
===============================

Sexual dysfunction affects up to 95% of women with MS,^[@bibr268-1756286420936166],[@bibr269-1756286420936166]^ but it is rarely discussed in the office setting. Many patients are embarrassed to bring up the topic, while many physicians feel that they have little to offer and do not ask. Nevertheless, sexual satisfaction is heavily linked to quality of life for women with MS,^[@bibr270-1756286420936166]^ and it is important for care providers to help manage this.

Female sexuality is multifaceted, and MS can impact it at every level. Direct damage to the brain and spinal cord can impede desire, decrease vaginal sensation and lubrication, and impair orgasm, as well as contribute to pain with sex. Indirect factors impacting sexual function can include physical problems like bladder/bowel dysfunction, fatigue, weakness, and spasticity, as well as emotional problems like cognitive dysfunction or depression.^[@bibr271-1756286420936166]^

"Invisible" psychologic and emotional factors may also negatively impact sexuality. Desire, for women, is heavily correlated with stress levels, fatigue, relationship quality, and many other intangibles that are vulnerable in settings of chronic neurologic disease. Women with MS often struggle with body image. Many couples struggle as they cope with the physical, emotional, and financial stressors imposed by the disease, and subsequently experience deterioration of their sexual relationship.

Sexual problems may develop early in the course of MS, and tend to persist or worsen over time.^[@bibr268-1756286420936166],[@bibr272-1756286420936166]^ Nevertheless, many factors contributing to sexual dysfunction in MS can be effectively modified ([Table 6](#table7-1756286420936166){ref-type="table"}).^[@bibr273-1756286420936166]^

###### 

Contributors to sexual dysfunction in MS and management options.

![](10.1177_1756286420936166-table7)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Contributing factors                                  Management options
  ----------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pain                                                  Vaginal lubricant/moisturizers\
                                                        Low-dose vaginal estrogen\
                                                        Intra-vaginal DHEA\
                                                        Laser treatment for vaginal atrophy\
                                                        Pelvic floor physical therapy

  Comorbid medical problems (e.g., diabetes, obesity)   Treatment of gynecologic disorders, bladder and bowel incontinence\
                                                        Diagnosis and management of sleep disorders\
                                                        Depression management\
                                                        Weight loss\
                                                        Systemic hormones for menopause, when appropriate

  Medication side effects                               Manage anti-depressant associated sexual dysfunction\
                                                        Behavioral (exercise, vibratory stimulation, scheduling sexual activity)\
                                                        Acupuncture\
                                                        Pharmacologic (bupropion, sildenafil, cyproheptadine)\
                                                        Modification of medications

  Psychologic factors                                   Psychotherapy, CBT, individual/couples therapy\
                                                        Stress management

  Hypoactive desire                                     Education\
                                                        Books: "Better Sex through Mindfulness" (Lori Brotto), "Mating in\
                                                        Captivity" (Esther Perel), "Come As You Are" (Emily Nagoski)\
                                                        Apps: Meet Rosy, OMGYes\
                                                        Sex therapy (may include behavioral, CBT, mindfulness therapy)\
                                                        CNS medications (flibanserin, bupropion^[†](#table-fn8-1756286420936166){ref-type="table-fn"}^, buspirone^[†](#table-fn8-1756286420936166){ref-type="table-fn"}^)\
                                                        Hormone therapy (transdermal testosterone^[†](#table-fn8-1756286420936166){ref-type="table-fn"},\ [‡](#table-fn9-1756286420936166){ref-type="table-fn"}^)\
                                                        Behavioral modifications (exercise, erotica, vibratory or clitoral vacuum stimulation)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Limited evidence exists to support these treatment options; these medications are not FDA-approved for hypoactive sexual desire in women.

Safety is incompletely understood in this population so risks and benefits should be considered.

CBT, cognitive behavioral therapy; DHEA, dehydroepiandrosterone; MS, multiple sclerosis.

Conclusion {#section30-1756286420936166}
==========

Sex hormones play a significant role in the risk and course of MS. Dramatic hormonal fluctuations can influence clinical, radiographic, and disability-related disease parameters. The role of sex chromosomes on sex differences in MS risk and disease progression represents a new frontier for exploration. More research efforts are needed to fully understand unique questions related to MS and fertility, contraception, pregnancy, and reproductive aging.
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